BWX Technologies, Inc. completes acquisition of Nordion (Canada) Inc.’s medical isotope business

On July 30, 2018, BWX Technologies, Inc. (NYSE:BWXT) (BWXT), a leading supplier of nuclear components and services, completed the acquisition of the medical isotope business of Nordion (Canada) Inc. (Nordion) from private-equity owned Sotera Health LLC (Sotera Health). This transformative acquisition supports BWXT’s entry into the radioisotopes industry with the development of a breakthrough proprietary technology to provide a stable, clean and cost-disruptive North American supply of critical medical isotopes and radiopharmaceuticals for research, diagnostic and therapeutic uses. The acquisition from Nordion adds licensed infrastructure, approximately 150 highly trained and experienced personnel, and two production centers (in Kanata and British Columbia) to BWXT’s business. 

BWXT was represented in-house by Ronald (Chip) Whitford and by Stikeman Elliott LLP with a team that included John Leopold, Warren Silversmith, Jeremy Sculnick, Marc-William Carrothers and Anne-Marie Panzini (M&A), Larry Cobb (nuclear and environmental), Mario Paura and Scott Brasil (real estate), Natasha vandenHoven and Allyson Marta (pension and benefits), Nancy Ramalho (employment), Frank Mathieu and Philippe Kattan (tax), Jonathan Auerbach (IP), Ryan Sheahan and Jessica Rutledge (health regulatory), and Jeffrey Brown and Ashley Piotrowski (regulatory). 

Nordion and Sotera Health were represented in-house by Matthew Klaben and Neil Gotfrit and by Cleary Gottlieb Steen & Hamilton LLP with a team that included Matthew Salerno, Gloria Ho Daniel Canavan and Sabria Cornish (M&A), Daniel Ilan, Jane Rosen and Michelle Elsner (IP), Michael Albano and Laura Bagarella (employee benefits), Daniel Culley and Jillian Chou (antitrust), Jason Factor and Derek Wallace (tax), Margaret (Meme) Peponis and Katherine Reaves (finance) as well as by Fasken Martineau DuMoulin LLP with a team that included Scott Conover, Andrew Alleyne, Jack Yu, Valerie Eisen and Ryan Schnier (M&A), Christopher Steeves and Paul Casuccio (tax), Huy Do (antitrust), Dan Law (real estate), Ingrid VanderElst (regulatory), Rosalind Cooper (environmental), Katherine Pollock (employment), Ross Gascho (employee benefits), Armand Benitah (IP), and by Morgan, Lewis & Bockius LLP with a team that included John Matthews and Alex Polonsky (nuclear regulatory), and Jaqueline Berman and Michele Buenafe (FDA).